NRG-GY026: Stage 1-IV Endometrial Serous Carcinoma or Carcinosarcoma - Clinical Trial

¿Cuál es el Propósito de este estudio?

We are doing this study to find out if adding drugs that target HER2 proteins to the standard therapy for endometrial cancer can improve the chance of remission or lower the risk that the cancer comes back after treatment. We want to know how well patients do on the standard treatment compared to two experimental study regimens.

¿Cuál es la Condición que se está estudiando?

HER2+ Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

¿Quién puede participar en el Estudio?

Adult females who:

Are diagnosed with Stage IA-IVB, non-recurrent, HER2-positive endometrial serous carcinoma or endometrial carcinosarcoma
Have not been treated with chemotherapy yet

For more information about who can join this study, please contact the study team at nick.jeffries@duke.edu.

Grupo etario

Adultos

¿Qué Implica?

If you decide to participate in this study, you will get an assignment to 1 of 3 groups:

Group 1: You will get paclitaxel and carboplatin by infusion through a vein (IV) for 18 weeks (standard treatment)
Group 2: You will get paclitaxel and carboplatin by infusion plus HERCEPTIN HYLECTA by injection under the skin (shots) for 18 weeks with the possibility of continuing for up to a year (study regimen)
Group 3: You will receive paclitaxel and carboplatin by infusion plus PHESGO by injection under the skin for 18 weeks with the possibility of continuing for up to a year (study regimen)

Detalles del Estudio

Título Completo

NRG-GY026:A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

Investigador Principal